Seattle-based company, Resolve Therapeutics, has developed a therapy for lupus that eliminates the initial critical events that trigger downstream pro-inflammatory events in people with lupus. Their research is evaluating patients with lupus who have active skin disease and elevated RNA-containing autoantibodies, measuring the percent of subjects with improvement in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score, compared to placebo because lupus skin disease activity is more sensitive to detecting change in disease activity.  

The company has completed enrollment of 64 patients into a double-blind, placebo-controlled study to evaluate the efficacy and safety of RSLV-132 for the treatment of people with systemic lupus erythematosus. Participants were recruited through 20 centers throughout the US and the biologic therapy is administered as 13 bi-weekly infusions over six months. Continue to follow the Foundation for updates on RSLV-132.
 

Read this study